Cargando…

Posterior reversible encephalopathy syndrome in a renal transplanted patient

Patient: Male, 28 Final Diagnosis: Posterior reversible encephalopathy syndrome Symptoms: Headache • pain around umblical region • seizures • visual disturbances Medication: Mycophenolate mofetil Clinical Procedure: Treatment of parasitosis • antiepileptic treatment • control of hypertension • chang...

Descripción completa

Detalles Bibliográficos
Autores principales: Alparslan, Merdin, Bora, Uslu, Hüseyin, Koçak, Ayhan, Dinçkan, Gültekin, Süleymanlar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711906/
https://www.ncbi.nlm.nih.gov/pubmed/23861991
http://dx.doi.org/10.12659/AJCR.889260
_version_ 1782276986144555008
author Alparslan, Merdin
Bora, Uslu
Hüseyin, Koçak
Ayhan, Dinçkan
Gültekin, Süleymanlar
author_facet Alparslan, Merdin
Bora, Uslu
Hüseyin, Koçak
Ayhan, Dinçkan
Gültekin, Süleymanlar
author_sort Alparslan, Merdin
collection PubMed
description Patient: Male, 28 Final Diagnosis: Posterior reversible encephalopathy syndrome Symptoms: Headache • pain around umblical region • seizures • visual disturbances Medication: Mycophenolate mofetil Clinical Procedure: Treatment of parasitosis • antiepileptic treatment • control of hypertension • changing mycophenolate mofetil to everolimus Specialty: Transplantology OBJECTIVE: Unusual or unexpected effect of treatment BACKGROUND: Posterior reversible encephalopathy syndrome (PRES) is characterized by reversible neurological findings with clinical hallmarks such as headache, confusion, seizures, cortical visual disturbances, and other focal neurological signs. CASE REPORT: A 28-year-old male patient was hospitalized secondary to diarrhea and abdominal pain. He had renal transplantation due to renal amyloidosis secondary to familial Mediterranean fever (FMF). In his clinical follow-up, he had seizures, hemiparesis, blurred vision, and vomited an Ascaris lumbricoides. MRI results led to diagnosis of PRES. Mycophenolate mofetil was changed to everolimus, his systolic blood was pressure kept below 140 mm hg, and his intestinal parasitosis was treated. During follow-up, he had no pain and no diarrhea. His neurological symptoms turned to normal within 48 hours and neuroradiological findings returned to normal within 2 weeks. CONCLUSIONS: PRES is a rare disorder of unknown incidence in renal transplantation patients. Early diagnosis is very important to prevent irreversible neurological sequelae. PRES is totally reversible with cessation of the offending agent, rapid control of hypertension, and treatment of the underlying disease. For early diagnosis and to reduce morbidity and mortality, stool sample examination should be made in patients taking immunosuppressive drugs.
format Online
Article
Text
id pubmed-3711906
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-37119062013-07-16 Posterior reversible encephalopathy syndrome in a renal transplanted patient Alparslan, Merdin Bora, Uslu Hüseyin, Koçak Ayhan, Dinçkan Gültekin, Süleymanlar Am J Case Rep Articles Patient: Male, 28 Final Diagnosis: Posterior reversible encephalopathy syndrome Symptoms: Headache • pain around umblical region • seizures • visual disturbances Medication: Mycophenolate mofetil Clinical Procedure: Treatment of parasitosis • antiepileptic treatment • control of hypertension • changing mycophenolate mofetil to everolimus Specialty: Transplantology OBJECTIVE: Unusual or unexpected effect of treatment BACKGROUND: Posterior reversible encephalopathy syndrome (PRES) is characterized by reversible neurological findings with clinical hallmarks such as headache, confusion, seizures, cortical visual disturbances, and other focal neurological signs. CASE REPORT: A 28-year-old male patient was hospitalized secondary to diarrhea and abdominal pain. He had renal transplantation due to renal amyloidosis secondary to familial Mediterranean fever (FMF). In his clinical follow-up, he had seizures, hemiparesis, blurred vision, and vomited an Ascaris lumbricoides. MRI results led to diagnosis of PRES. Mycophenolate mofetil was changed to everolimus, his systolic blood was pressure kept below 140 mm hg, and his intestinal parasitosis was treated. During follow-up, he had no pain and no diarrhea. His neurological symptoms turned to normal within 48 hours and neuroradiological findings returned to normal within 2 weeks. CONCLUSIONS: PRES is a rare disorder of unknown incidence in renal transplantation patients. Early diagnosis is very important to prevent irreversible neurological sequelae. PRES is totally reversible with cessation of the offending agent, rapid control of hypertension, and treatment of the underlying disease. For early diagnosis and to reduce morbidity and mortality, stool sample examination should be made in patients taking immunosuppressive drugs. International Scientific Literature, Inc. 2013-07-10 /pmc/articles/PMC3711906/ /pubmed/23861991 http://dx.doi.org/10.12659/AJCR.889260 Text en © Am J Case Rep, 2013 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License
spellingShingle Articles
Alparslan, Merdin
Bora, Uslu
Hüseyin, Koçak
Ayhan, Dinçkan
Gültekin, Süleymanlar
Posterior reversible encephalopathy syndrome in a renal transplanted patient
title Posterior reversible encephalopathy syndrome in a renal transplanted patient
title_full Posterior reversible encephalopathy syndrome in a renal transplanted patient
title_fullStr Posterior reversible encephalopathy syndrome in a renal transplanted patient
title_full_unstemmed Posterior reversible encephalopathy syndrome in a renal transplanted patient
title_short Posterior reversible encephalopathy syndrome in a renal transplanted patient
title_sort posterior reversible encephalopathy syndrome in a renal transplanted patient
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3711906/
https://www.ncbi.nlm.nih.gov/pubmed/23861991
http://dx.doi.org/10.12659/AJCR.889260
work_keys_str_mv AT alparslanmerdin posteriorreversibleencephalopathysyndromeinarenaltransplantedpatient
AT borauslu posteriorreversibleencephalopathysyndromeinarenaltransplantedpatient
AT huseyinkocak posteriorreversibleencephalopathysyndromeinarenaltransplantedpatient
AT ayhandinckan posteriorreversibleencephalopathysyndromeinarenaltransplantedpatient
AT gultekinsuleymanlar posteriorreversibleencephalopathysyndromeinarenaltransplantedpatient